Hao Wen

Dr. Hao Wen

orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2022 in Cellular Signalling
Verified
Journal Article
Open access
ZWZongding Wang
Zongding Wang
TJTiemin Jiang
Tiemin Jiang
TATuerganaili Aji
Tuerganaili Aji
KAKalibixiati Aimulajiang
Kalibixiati Aimulajiang
YLYanshi Liu
Yanshi Liu
HWHao Wen
Hao Wen
Hepatic regeneration after hepatectomy is a great concern in clinical practice. Recently, the neuronal guidance protein netrin-1 has been reported to enhance regeneration after nerve injury. The goal of this study was to preliminarily investigate whether netrin-1 stimulates vagus nerve regeneration to promote liver regeneration after partial hepatectomy in mice. The expression of netrin-1 in murine remnant livers after partial hepatectomy (PHx) was evaluated in initial studies. C57BL/6 mice that received exogenous netrin-1 after PHx were used to examine liver regeneration. PHx was performed in wild-type mice after adeno-associated virus injection (Ntn1 gene silencing) to detect the impact of endogenous netrin-1. After PHx and hepatic branch vagotomy (HV), the mice were injected with or without netrin-1 to evaluate the effects on hepatic regeneration and vagal nerve recovery. Significant reductions in netrin-1 at the transcript and protein levels in murine liver tissue after hepatectomy were observed. Subsequent studies of netrin-1 administration revealed the promotion of hepatocyte proliferation and specific growth factors contributing to liver repair and a decrease in hepatic-specific injury enzymes. Furthermore, the opposite results were observed in the netrin-1 knockdown group. HV delayed liver regeneration after PHx. However, this retardation was reversed by exogenous netrin-1 supplementation. In addition, the results of nerve growth and vagal nerve repair in the remnant liver suggested that netrin-1 promoted vagal nerve regeneration after hepatectomy. Netrin-1 accelerates liver regeneration after partial hepatectomy in mice, and the potential mechanism is related to the promotion of vagus nerve repair and regeneration.

1 January 1997 in Japanese Journal of Medical Science and Biology
Verified
Journal Article
Open access
PDF file
AIAkira Ito
Akira Ito
HWHao Wen
Hao Wen
PCPhilip S. Craig
Philip S. Craig
LMLiang Ma
Liang Ma
MNMinoru Nakao
Minoru Nakao
YLYue-Han Liu
Yue-Han Liu
Western blot analysis was carried out in order to evaluate new serodiagnostic markers, Em18 and Em16, for differentiation of alveolar echinococcosis (AE) from cystic echinococcosis (CE) using 36 serum samples from hydatid patients from Xinjiang, China, where AE and CE are both endemic and one double infection case has been reported. All AE cases except one (5/6) who exhibited a calcified lesion and a single case of double infection showed antibody responses against Em18 and Em16. Some of CE patient sera (6/22) showed antibody response against Em16 except one who showed that against Em18. Analyses of IgG subclass responses against Em18 and Em16 were carried out us-ing all serum samples showing antibody responses against Em18 and/or Em16 (seven CE, five AE, and one AE+CE) and additional samples of three CE and 22 AE from Sichuan, China. IgG4 was the most predominant antibody subclass. Em18 and Em16 were recognized by both IgG4 and IgG1 (in most cases) or by either IgG4 or IgG1 (in minor cases) or by IgG3 (in very rare cases) . Neither Em18 nor Em16 was recognized by IgG2 antibodies. The usefulness of Em18 and Em16 as potential new markers for serological differentiation of human AE and CE, respectively, is discussed.

13 June 2022 in Frontiers in Pharmacology
Verified
Journal Article
Open access
JLJunyuan Lv
Junyuan Lv
XLXintong Li
Xintong Li
HWHongyu Wu
Hongyu Wu
JLJiayang Li
Jiayang Li
BLBoyang Luan
Boyang Luan
HWHao Wen
Hao Wen
Vascular smooth muscle cell (VSMC) phenotypic transition represents the fundamental pathophysiological alteration in the vascular remodeling process during the initiation and progression of cardiovascular diseases. Recent studies have revealed that Icariside II (ICS-II), a flavonol glycoside derived from the traditional Chinese medicine Herba Epimedii, exhibited therapeutic effects in various cardiovascular diseases. However, the therapeutic efficacy and underlying mechanisms of ICS-II regarding VSMC phenotypic transition were unknown. In this study, we investigated the therapeutic effects of ICS-Ⅱ on vascular remodeling with a rat’s balloon injury model in vivo. The label-free proteomic analysis was further implemented to identify the differentially expressed proteins (DEPs) after ICS-II intervention. Gene ontology and the pathway enrichment analysis were performed based on DEPs. Moreover, platelet-derived growth factor (PDGF-BB)-induced primary rat VSMC was implemented to verify the restoration effects of ICS-II on the VSMC contractile phenotype. Results showed that ICS-II could effectively attenuate the vascular remodeling process, promote SMA-α protein expression, and inhibit OPN expression in vivo. The proteomic analysis identified 145 differentially expressed proteins after ICS-II intervention. Further, the bioinformatics analysis indicated that the focal adhesion signaling pathway was enriched in the ICS-II group. In vitro studies showed that ICS-II suppressed VSMC proliferation and migration, and promoted VSMC contractile phenotype by modulating the focal adhesion signaling pathway. Taken together, our results suggest that ICS-II attenuates the vascular remodeling process and restores the VSMC contractile phenotype by promoting the focal adhesion pathway.

11 December 2025 in European Journal of Vascular and Endovascular Surgery
Verified
Journal Article
Closed access
HWHao Wen
Hao Wen
JWJianming Wang
Jianming Wang
JLJiaqi Li
Jiaqi Li
MYMeiyu Yu
Meiyu Yu
YSYihan Sun
Yihan Sun
LWLei Wang
Lei Wang

8 December 2025 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
YSYihan Sun
Yihan Sun
JLJiaqi Li
Jiaqi Li
XCXinyue Cui
Xinyue Cui
MYMeiyu Yu
Meiyu Yu
BXBoying Xiao
Boying Xiao
HWHao Wen
Hao Wen
Background: Traumatic brain injury (TBI) represents a major global health challenge. Several clinical studies have suggested that Xuebijing (XBJ)—a patented Chinese botanical drug preparation may confer neuroprotective and anti-inflammatory benefits in TBI. This systematic review and meta-analysis aimed to evaluate the therapeutic efficacy and safety of XBJ as an adjunctive treatment for TBI. Materials and methods: A comprehensive search was performed across nine English and Chinese databases for randomized controlled trials (RCTs) evaluating XBJ in TBI patients, with records screened up to February 2025. Two independent reviewers conducted study selection and data extraction. Pooled estimates were calculated using fixed- or random-effects models, expressed as standardized mean differences (SMDs) or risk ratios (RRs) with 95% confidence intervals (CIs). Trial sequential analysis (TSA) and the GRADE framework were used to assess evidence robustness and certainty. Subgroup and sensitivity analyses explored potential dose–response patterns and sources of heterogeneity. Results: A total of 33 RCTs involving 3,215 patients with TBI met the inclusion criteria. Pooled analysis demonstrated that XBJ significantly improved neurological function, yielding higher Glasgow Coma Scale (GCS) scores (SMD = 0.66, 95% CI 0.51–0.80) and Glasgow Outcome Scale (GOS) scores (SMD = 0.78, 95% CI 0.39–1.16), while reducing all-cause mortality (RR = 0.56, 95% CI 0.44–0.69). XBJ also markedly decreased systemic inflammatory biomarkers, including C-reactive protein (CRP; SMD = −1.34), tumour necrosis factor-alpha (TNF-α; SMD = −0.98), and interleukin-6 (IL-6; SMD = −0.98) (all p < 0.01). No significant increase in adverse drug events (ADEs) was observed (RR = 1.32, 95% CI 0.58–2.96). Subgroup analyses indicated a dose-dependent relationship, with cumulative doses >1,400 mL and twice-daily intravenous administration associated with greater neurological and anti-inflammatory benefits. Conclusion: XBJ appears to be an effective and safe adjunctive therapy for TBI, improving neurological outcomes and reducing inflammatory responses. Dose-dependent effects support the optimization of treatment protocols.

20 May 2025 in Annals of Medicine & Surgery
Verified
Journal Article
Open access
JLJiaqi Li
Jiaqi Li
LWLei Wang
Lei Wang
ZLZiqi Li
Ziqi Li
YSYihan Sun
Yihan Sun
MYMeiyu Yu
Meiyu Yu
HWHao Wen
Hao Wen
Background: Hand, foot, and mouth disease (HFMD) is a viral infection, primarily caused by gastrointestinal viruses. Xuebijing (XBJ) injection, widely used in China for treating inflammatory conditions like sepsis, may offer therapeutic benefits for HFMD. This study aimed to evaluate the efficacy and safety of adjunctive XBJ therapy for HFMD. Materials and methods: Databases were systematically searched until February 2024. Meta-analysis used random or fixed-effect models, with outcomes reported as standardized mean differences (SMD) or relative risks (RR) and 95% confidence intervals (CI). Heterogeneity was assessed via Cochran’s Q test and I 2 index. Network pharmacology, molecular docking, and molecular dynamics simulations identified active XBJ components and their targets in HFMD. Results: Six randomized controlled trials (RCTs) involving 786 participants were included. XBJ significantly improved the total effective rate (RR = 1.19, P < 0.01), shortened fever duration (SMD = − 1.78, P < 0.01), reduced rash resolution time (SMD = − 1.13, P < 0.01), and decreased hospital stay (SMD = − 1.20, P < 0.01). Pharmacological analysis identified four active XBJ components targeting IFN-γ, TLR4, and TNF-α in HFMD. Conclusions: XBJ as adjunctive therapy improves outcomes in HFMD and is safe, with specific molecular targets identified for its therapeutic effects.